PRACTICAL PEARLS: C. difficile infection (CDI)
INTRODUCTION





INITIAL EVALUATION
AND MANAGEMENT
BY PRIMARY CARE







Caused by the stool bacteria Clostridium difficile
Increasing incidence in pediatrics over the past 15-20 years
Presenting symptoms: watery diarrhea (with or without blood), crampy abdominal pain,
and fevers that may range from low-grade to high-grade
Risk factors for pediatric CDI: antibiotic use within the past 30 days, current/recent
inpatient hospitalization > 7 days, recent bowel surgery/GI tract manipulation (including
prolonged NG tube insertion, tube feedings, and gastrostomy tube presence), immune
suppression, exposure to those infected and/or colonized with C. difficile
Consider obtaining stool testing from children older than 12 months with suspicious
clinical symptoms and > 1 risk factors for CDI
Testing is not recommended for children < 12 months, due to high rates of
asymptomatic C. difficile carriage in this age group
Oral metronidazole – initial treatment for mild-to-moderate disease, while oral
vancomycin – initial therapy for severe disease, or for those who do not respond to
metronidazole
AAP Policy statement on pediatric CDI:
http://pediatrics.aappublications.org/content/131/1/196
IDSA Guidelines:
http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_by_Organism/Bacteria/Clostri
dium_difficile/

WHEN TO REFER




Questions about appropriate indications for testing, alternative diagnoses, optimal
antibiotic selection and duration of treatment
Previously treated patients with refractory or recurrent CDI

HOW TO REFER




794-KIDS – Request Pediatric Infectious Diseases appointments
For more urgent access, please call the Pedi ID doctor on call

WHAT TO EXPECT
FROM BAYSTATE
CHILDREN’S
HOSPITAL VISIT



Current patient information and pertinent medical records from the primary care office
will be requested prior to the visit for review
Due to the nature of some patients’ symptoms, other referrals such as gastroenterology,
or possible inpatient admission for additional evaluation and treatment may be
recommended
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